SAN DIEGO Fixing genetic diseases such as hemophilia, sickle-cell disease, and certain immunodeficiencies at their root, by replacing or repairing the faulty gene, has gone from dream to drug, with two gene therapies now approved in Europe, and a number of additional approvals expected on both sides of the Atlantic over the next few years.more »
Parkinson's disease (PD) has joined the list of disorders that are affected by the gut microbiome. In studies reported in the Dec. 1, 2016, issue of Cell, researchers showed that signals from the gut microbiome affected the level of neuroinflammation and the degree of motor dysfunction in an animal model of PD.
DUBLIN – PCSK9 inhibitors are as good as but no better than statins in reducing the risk of cardiovascular events in patients with cardiovascular disease, according to a large-scale Mendelian randomization study published this week in the New England Journal of Medicine. more »
- Selecta's synthetic vaccine particles platform 'Spark's interest, results in $2.18B licensing d...
- Editing set to broaden genetic blood fixes
- Much-needed optimism coming to AML space
- Harnessing precision medicine to BEAT acute myeloid leukemia
- Gazyva tops Rituxan in PFS in first-line FL, but safety, OS data lag
- Innovent's $260M private financing is China's largest ever for a biopharma
- Smog alert: Pollution around Beijing halts drug manufacturing
- Singapore's Cellresearch advances wound healing stem cell treatment
- Privacy in the genomics age: A unique ethics debate in Islamic world
- After IPO, new deals, Adalta entering clinic wit...
With just one month to go before biopharma draws the curtains on a year that has seen its fair share of lows for the sector, it received an early Christmas present following Donald Trump's unexpected victory in the presidential election. Share values of drug developers have soared in the wake of the result because it came with the removal, at least for now, of fears that drug-pricing policy issues will be high on the political agenda going forward.
"Basically, it's not easy to define what will serve humanity."
So said Yoshinori Ohsumi, honorary professor at the Tokyo Institute of Technology, after winning the 2012 Kyoto Prize in Life Sciences for his research.
The Nobel Assembly followed suit in recognizing the importance of Ohsumi's work, awarding him the 2016 Nobel Prize in Physiology or Medicine to "for his discoveries of mechanisms for autophagy."READ MORE »
- First steps taken toward neutralizing Zika virus »
- Medicine's future is precise, if still uncertain »
- Quorum sensing controls adaptive immunity via CRISPR »
- Tau phosphorylation inhibits plaque toxicity in AD mice »
- Drug shows promise in preventing pre-term birth in mice »
- Cachexia is linked to immunotherapy failure »
- Circuit-specific receptor targeting fights epilepsy »
- Bacterial metabolite shows activity in breast cancer »
- Stimulating, blocking rapid-acting estrogen receptor both beneficial »
- Time for fa-la-la with BioWorld’s 10th annual Holiday Gift GuideDecember 02, 2016 | 8:43 PM | Posted by: Marie Powers
- Biotech’s biggest protesters are turning into its supporters November 30, 2016 | 10:58 PM | Posted by: Amanda Lanier
- Sex and drugs: Something doesn’t ‘Addyi’ upNovember 04, 2016 | 10:35 PM | Posted by: Randy Osborne
- Rules of the PAP road not always clear, even to seasoned travelersOctober 25, 2016 | 11:37 PM | Posted by: Marie Powers
- Left on the garbage heap of the 114th Congress?September 02, 2016 | 4:57 PM | Posted by: Mari Serebrov
Partners in Focus
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter